Advertisement

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Opportunities to Optimize Cancer Policies Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Aug
02
Today In Oncology
ACS Study Quantifies Financial Burden of Cancer in Older Patients
Transplant Consolidation Improves Survival in Primary CNS Lymphoma
Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL
NCI Names New CCR Director
Rectal Cancer AI Identifies Patients Most Likely to Benefit From Irinotecan-Intensified Neoadjuvant Chemoradiotherapy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo